Cooley Recognized With Four 2025 China Business Law Awards

Hong Kong, Beijing, Shanghai and Singapore – August 13, 2025 – China Business Law Journal (CBLJ) honored Cooley in its China Business Law Awards 2025, which recognize the best Chinese and international law firms in various practice area categories for the Chinese market.

Cooley was newly listed among the leading outbound M&A practices, noted specifically for its work representing the biopharmaceutical company Nuvation Bio in its acquisition of AnHeart Therapeutics.

The firm also earned two honors for the seventh consecutive year, receiving recognition as a top international firm in the Healthcare, Pharma and Life Sciences category and the Private Equity and Venture Capital category. In conferring the former honor, CBLJ noted Cooley’s representation of ProfoundBio in its $1.8 billion acquisition by Genmab and its representation of Chimagen Biosciences in its $850 million dual-target licensing deal with GSK. It also noted the firm’s advising of Jiangsu Hengrui Pharmaceuticals, one of the largest pharmaceutical companies in China, on its licensing of global rights (excluding Greater China) to its proprietary glucagon-like peptide-1 drugs for $6 billion and its acquisition of a 19.9% equity stake in Hercules CM Newco.

Lastly, Cooley was listed among the top international firms in the inaugural Legaltech Pioneers category.

Cooley’s Beijing, Hong Kong and Shanghai offices represent a growing number of China’s most innovative and dynamic tech and life sciences companies, advising them from formation through financing and exit. The teams’ in-depth subject matter knowledge and transactional prowess enable the firm to handle a raft of corporate, finance, M&A and capital markets work for international and China-based high-tech and life sciences entities engaged in inbound and outbound endeavors.

Cooley’s Singapore-based team has worked on numerous significant corporate deals, guiding clients on financings, M&A, joint ventures, and capital markets and other strategic transactions. At the time of its opening in 2020, the Singapore office was Cooley’s fourth in the Asia-Pacific region, its first in Southeast Asia and its 16th office worldwide.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.